Results 171 to 180 of about 381,135 (230)
Some of the next articles are maybe not open access.
Journal of Vascular Nursing, 1997
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
HEPARIN, LOW MOLECULAR WEIGHT HEPARIN, AND HEPARIN ANALOGUES
British Journal of Haematology, 1984D. Thomas
openaire +3 more sources
Medical Clinics of North America, 1994
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
The Journal of Urology, 1997
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides
Clinics in Geriatric Medicine, 2006Elderly patients require special consideration when administered anticoagulants because of age-related alterations in renal function, protein binding, and increased bleeding risk. Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation.
Danya L, Dinwoodey, Jack E, Ansell
openaire +2 more sources
Drugs & Aging, 1992
The introduction of low molecular weight heparins has added a new dimension to the management of thrombotic disorders. Ten LMWHs are currently available for clinical use. Although these agents have been primarily developed and used in European countries, other countries, including the US, have started to evaluate their usefulness.
D, Hoppensteadt, J M, Walenga, J, Fareed
openaire +2 more sources
The introduction of low molecular weight heparins has added a new dimension to the management of thrombotic disorders. Ten LMWHs are currently available for clinical use. Although these agents have been primarily developed and used in European countries, other countries, including the US, have started to evaluate their usefulness.
D, Hoppensteadt, J M, Walenga, J, Fareed
openaire +2 more sources
Low molecular weight heparin, heparin, and warfarin
Current Opinion in Hematology, 1995Low molecular weight heparin is effective for the prevention and treatment of venous thromboembolism. Low molecular weight heparin has the practical advantage that it does not require anticoagulant monitoring and dose adjustment. The simplified therapy provided by low molecular weight heparin may allow many patients with venous thromboembolism to be ...
openaire +2 more sources
Archives of Internal Medicine, 1993
HEARIN WAS first described in 1916 by McLean 1 who was working in the laboratory of Dr William Howell. McLean was given the assignment to extract thromboplastin from various animal tissues. Ironically, rather than isolating procoagulant thromboplastin, he was successful in extracting an anticoagulant. Following his discovery, heparin was found to be an
openaire +2 more sources
HEARIN WAS first described in 1916 by McLean 1 who was working in the laboratory of Dr William Howell. McLean was given the assignment to extract thromboplastin from various animal tissues. Ironically, rather than isolating procoagulant thromboplastin, he was successful in extracting an anticoagulant. Following his discovery, heparin was found to be an
openaire +2 more sources
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly